Xenon Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Xenon Pharmaceuticals is a biopharmaceutical organization zeroed in on the improvement of novel drugs through the utilization of our restrictive revelation stage, which we allude to as Extreme Genetics. Our item applicants depend on hereditary experiences got from our examination of families where people display serious characteristics or aggregates. They apply their mastery to foresee which aggregates are brought about by single-quality deformities. By recognizing and describing the single-quality deformities liable for such serious aggregates, they gain significant experiences into their capability in human science and their true capacity as medication targets. Considering that these objectives are many times engaged with illnesses past the uncommon hereditary problems in which they are first distinguished, they are creating exclusive item contender to regard the two vagrants as well as additional common sicknesses
Xenon Pharmaceuticals has raised $1.1B across 3 funding rounds on record, the most recent an undisclosed round of $551M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Xenon Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Xenon Pharmaceuticals Funding Rounds
Xenon Pharmaceuticals raised $300M in a Post-IPO Equity announced in Oct 2021.
8 months later, a Post-IPO Equity of $288M was announced in Jun 2022.
3.8 years later, an undisclosed round of $551M was announced in Mar 2026.
Xenon Pharmaceuticals Founders and Leadership Team
Contact details for the Xenon Pharmaceuticals team: 2 of 2 have an email address on file.
Start 14-day free trial →Xenon Pharmaceuticals Funding Compared to Other Biotechnology Startups
Xenon Pharmaceuticals' latest round of $551M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Xenon Pharmaceuticals in Biotechnology and Burnaby
Companies Similar to Xenon Pharmaceuticals
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Xenon Pharmaceuticals Funding FAQs
What does Xenon Pharmaceuticals do?
Xenon Pharmaceuticals is a biopharmaceutical organization zeroed in on the improvement of novel drugs through the utilization of our restrictive revelation stage, which we allude to as Extreme Genetics. Our item applicants depend on hereditary experiences got from our examination of families where people display serious characteristics or aggregates. They apply their mastery to foresee which aggregates are brought about by single-quality deformities. By recognizing and describing the single-quality deformities liable for such serious aggregates, they gain significant experiences into their capability in human science and their true capacity as medication targets. Considering that these objectives are many times engaged with illnesses past the uncommon hereditary problems in which they are first distinguished, they are creating exclusive item contender to regard the two vagrants as well as additional common sicknesses
How much funding has Xenon Pharmaceuticals raised?
Xenon Pharmaceuticals has raised $1.1B across 3 rounds on record. The most recent is an undisclosed round of $551M announced in Mar 2026.
When did Xenon Pharmaceuticals last raise funding?
Xenon Pharmaceuticals' most recent funding round on record is an undisclosed round of $551M, announced in Mar 2026.
Who is the CEO of Xenon Pharmaceuticals?
Ian Mortimer is listed as CEO at Xenon Pharmaceuticals.
Where is Xenon Pharmaceuticals headquartered?
Xenon Pharmaceuticals is based in Burnaby, British Columbia, Canada.
How many employees does Xenon Pharmaceuticals have?
Xenon Pharmaceuticals is in the 101-250 employee band.
How does Xenon Pharmaceuticals' funding compare to other Biotechnology startups?
Xenon Pharmaceuticals' latest round of $551M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Xenon Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Xenon Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.